Infliximab use in Crohn's disease: Impact on health care resources in the UK

Derek P. Jewell; Jack Satsangi; Alan Lobo; Christopher Probert; Alastair Forbes; Subrata Ghosh; Jon Shaffer; Markus Frenz; Hazel Drummond; Gill Troy; Sue Turner; Lisa Younge; Lyn Evans; Mark Moosa; Barry Rodgers-Gray; Scot Buchan

doi:10.1097/00042737-200510000-00007

Infliximab use in Crohn's disease: Impact on health care resources in the UK

Derek P. Jewell
, Jack Satsangi
, Alan Lobo
, Christopher Probert
, Alastair Forbes
, Subrata Ghosh
, Jon Shaffer
, Markus Frenz
, Hazel Drummond
, Gill Troy
, Sue Turner
, Lisa Younge
, Lyn Evans
, Mark Moosa
, Barry Rodgers-Gray
, Scot Buchan

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

Abstract

To quantify the impact of infliximab therapy on health care resource utilization in the UK.

Original language	English
Pages (from-to)	1047-52
Number of pages	6
Journal	European Journal of Gastroenterology & Hepatology
Volume	17
Issue number	10
DOIs	https://doi.org/10.1097/00042737-200510000-00007
Publication status	Published - Oct 2005

Keywords

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antirheumatic Agents
Cost-Benefit Analysis
Crohn Disease
Drug Costs
Epidemiologic Methods
Female
Great Britain
Health Care Costs
Health Resources
Health Services Research
Hospitalization
Humans
Male
Middle Aged
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1097/00042737-200510000-00007

Cite this

Jewell, D. P., Satsangi, J., Lobo, A., Probert, C., Forbes, A., Ghosh, S., Shaffer, J., Frenz, M., Drummond, H., Troy, G., Turner, S., Younge, L., Evans, L., Moosa, M., Rodgers-Gray, B., & Buchan, S. (2005). Infliximab use in Crohn's disease: Impact on health care resources in the UK. European Journal of Gastroenterology & Hepatology, 17(10), 1047-52. https://doi.org/10.1097/00042737-200510000-00007

@article{31e9e7b6f21d40a98096eb58779ff778,

title = "Infliximab use in Crohn's disease: Impact on health care resources in the UK",

abstract = "To quantify the impact of infliximab therapy on health care resource utilization in the UK.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antirheumatic Agents, Cost-Benefit Analysis, Crohn Disease, Drug Costs, Epidemiologic Methods, Female, Great Britain, Health Care Costs, Health Resources, Health Services Research, Hospitalization, Humans, Male, Middle Aged, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Jewell, \{Derek P.\} and Jack Satsangi and Alan Lobo and Christopher Probert and Alastair Forbes and Subrata Ghosh and Jon Shaffer and Markus Frenz and Hazel Drummond and Gill Troy and Sue Turner and Lisa Younge and Lyn Evans and Mark Moosa and Barry Rodgers-Gray and Scot Buchan",

year = "2005",

month = oct,

doi = "10.1097/00042737-200510000-00007",

language = "English",

volume = "17",

pages = "1047--52",

journal = "European Journal of Gastroenterology \& Hepatology",

issn = "0954-691X",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

Jewell, DP, Satsangi, J, Lobo, A, Probert, C, Forbes, A, Ghosh, S, Shaffer, J, Frenz, M, Drummond, H, Troy, G, Turner, S, Younge, L, Evans, L, Moosa, M, Rodgers-Gray, B & Buchan, S 2005, 'Infliximab use in Crohn's disease: Impact on health care resources in the UK', European Journal of Gastroenterology & Hepatology, vol. 17, no. 10, pp. 1047-52. https://doi.org/10.1097/00042737-200510000-00007

TY - JOUR

T1 - Infliximab use in Crohn's disease: Impact on health care resources in the UK

AU - Jewell, Derek P.

AU - Satsangi, Jack

AU - Lobo, Alan

AU - Probert, Christopher

AU - Forbes, Alastair

AU - Ghosh, Subrata

AU - Shaffer, Jon

AU - Frenz, Markus

AU - Drummond, Hazel

AU - Troy, Gill

AU - Turner, Sue

AU - Younge, Lisa

AU - Evans, Lyn

AU - Moosa, Mark

AU - Rodgers-Gray, Barry

AU - Buchan, Scot

PY - 2005/10

Y1 - 2005/10

N2 - To quantify the impact of infliximab therapy on health care resource utilization in the UK.

AB - To quantify the impact of infliximab therapy on health care resource utilization in the UK.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal

KW - Antirheumatic Agents

KW - Cost-Benefit Analysis

KW - Crohn Disease

KW - Drug Costs

KW - Epidemiologic Methods

KW - Female

KW - Great Britain

KW - Health Care Costs

KW - Health Resources

KW - Health Services Research

KW - Hospitalization

KW - Humans

KW - Male

KW - Middle Aged

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

U2 - 10.1097/00042737-200510000-00007

DO - 10.1097/00042737-200510000-00007

M3 - Article

C2 - 16148549

SN - 0954-691X

VL - 17

SP - 1047

EP - 1052

JO - European Journal of Gastroenterology & Hepatology

JF - European Journal of Gastroenterology & Hepatology

IS - 10

ER -